Treatment of pneumonia in patients at risk of infection with gram-negative bacilli

J. Lucius McGehee, Steven D. Podnos, Alan K. Pierce, Jonathan C. Weissler

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Patients with a history of chronic debilitating disease due to a variety of causes are known to be at risk for infection with coliform gram-negative bacilli when they present with community-acquired pneumonia. Empiric treatment with broad-spectrum parenteral antibiotics is often begun in such patients pending the result of blood and other cultures. The optimal duration of broad-spectrum empiric therapy in such patients when cultures fail to reveal a specific pathogen is unknown. Review was made of the charts of 131 patients with community-acquired pneumonia admitted to the hospital and treated with broad-spectrum parenteral antibiotics in whom a specific pathogen was never isolated. Overall, 89 percent of these patients were cured without complication or relapse. Patients receiving broad-spectrum therapy for four days or less due to rapid clinical improvement had a successful outcome in 95 percent of cases. It is concluded that broad-spectrum parenteral antibiotic therapy can safely be abbreviated provided response to therapy is prompt.

Original languageEnglish (US)
Pages (from-to)597-602
Number of pages6
JournalThe American journal of medicine
Volume84
Issue number3 PART 2
DOIs
StatePublished - 1988

Fingerprint

Bacillus
Pneumonia
Infection
Anti-Bacterial Agents
Therapeutics
Chronic Disease
Recurrence

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Treatment of pneumonia in patients at risk of infection with gram-negative bacilli. / Lucius McGehee, J.; Podnos, Steven D.; Pierce, Alan K.; Weissler, Jonathan C.

In: The American journal of medicine, Vol. 84, No. 3 PART 2, 1988, p. 597-602.

Research output: Contribution to journalArticle

Lucius McGehee, J. ; Podnos, Steven D. ; Pierce, Alan K. ; Weissler, Jonathan C. / Treatment of pneumonia in patients at risk of infection with gram-negative bacilli. In: The American journal of medicine. 1988 ; Vol. 84, No. 3 PART 2. pp. 597-602.
@article{bf09aff3697440d596cd901d7cd0a30d,
title = "Treatment of pneumonia in patients at risk of infection with gram-negative bacilli",
abstract = "Patients with a history of chronic debilitating disease due to a variety of causes are known to be at risk for infection with coliform gram-negative bacilli when they present with community-acquired pneumonia. Empiric treatment with broad-spectrum parenteral antibiotics is often begun in such patients pending the result of blood and other cultures. The optimal duration of broad-spectrum empiric therapy in such patients when cultures fail to reveal a specific pathogen is unknown. Review was made of the charts of 131 patients with community-acquired pneumonia admitted to the hospital and treated with broad-spectrum parenteral antibiotics in whom a specific pathogen was never isolated. Overall, 89 percent of these patients were cured without complication or relapse. Patients receiving broad-spectrum therapy for four days or less due to rapid clinical improvement had a successful outcome in 95 percent of cases. It is concluded that broad-spectrum parenteral antibiotic therapy can safely be abbreviated provided response to therapy is prompt.",
author = "{Lucius McGehee}, J. and Podnos, {Steven D.} and Pierce, {Alan K.} and Weissler, {Jonathan C.}",
year = "1988",
doi = "10.1016/0002-9343(88)90142-8",
language = "English (US)",
volume = "84",
pages = "597--602",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "3 PART 2",

}

TY - JOUR

T1 - Treatment of pneumonia in patients at risk of infection with gram-negative bacilli

AU - Lucius McGehee, J.

AU - Podnos, Steven D.

AU - Pierce, Alan K.

AU - Weissler, Jonathan C.

PY - 1988

Y1 - 1988

N2 - Patients with a history of chronic debilitating disease due to a variety of causes are known to be at risk for infection with coliform gram-negative bacilli when they present with community-acquired pneumonia. Empiric treatment with broad-spectrum parenteral antibiotics is often begun in such patients pending the result of blood and other cultures. The optimal duration of broad-spectrum empiric therapy in such patients when cultures fail to reveal a specific pathogen is unknown. Review was made of the charts of 131 patients with community-acquired pneumonia admitted to the hospital and treated with broad-spectrum parenteral antibiotics in whom a specific pathogen was never isolated. Overall, 89 percent of these patients were cured without complication or relapse. Patients receiving broad-spectrum therapy for four days or less due to rapid clinical improvement had a successful outcome in 95 percent of cases. It is concluded that broad-spectrum parenteral antibiotic therapy can safely be abbreviated provided response to therapy is prompt.

AB - Patients with a history of chronic debilitating disease due to a variety of causes are known to be at risk for infection with coliform gram-negative bacilli when they present with community-acquired pneumonia. Empiric treatment with broad-spectrum parenteral antibiotics is often begun in such patients pending the result of blood and other cultures. The optimal duration of broad-spectrum empiric therapy in such patients when cultures fail to reveal a specific pathogen is unknown. Review was made of the charts of 131 patients with community-acquired pneumonia admitted to the hospital and treated with broad-spectrum parenteral antibiotics in whom a specific pathogen was never isolated. Overall, 89 percent of these patients were cured without complication or relapse. Patients receiving broad-spectrum therapy for four days or less due to rapid clinical improvement had a successful outcome in 95 percent of cases. It is concluded that broad-spectrum parenteral antibiotic therapy can safely be abbreviated provided response to therapy is prompt.

UR - http://www.scopus.com/inward/record.url?scp=0023968388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023968388&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(88)90142-8

DO - 10.1016/0002-9343(88)90142-8

M3 - Article

C2 - 3348268

AN - SCOPUS:0023968388

VL - 84

SP - 597

EP - 602

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 3 PART 2

ER -